Critically Ill Patients With ECMO Clinical Trial
Official title:
Pharmacokinetics of Imipenem in Critically Ill Patients With Life-threatening Severe Infections During Support With Extracorporeal Membrane Oxygenation
Extracorporeal membrane oxygenation (ECMO) has become increasingly used for lifesaving
respiratory and/or cardiac failure support in critically ill patients, including those with
life-threatening severe infections. This cardiopulmonary bypass device has been shown to
enhance the profound pathophysiological changes in this patient population, resulting in an
alteration of the pharmacokinetics (PK) of antimicrobial agents. The aim of this study was to
determine the effect of ECMO on the PK of imipenem in critically ill patients supported by
this cardiopulmonary bypass device.
Methods The study was conducted in critically ill patients with respiratory and/or cardiac
failure and suspected severe nosocomial infections who were supported by ECMO. All patients
received a 1-h infusion of 0.5 g of imipenem every 6 h and imipenem PK studies were carried
out on the fourth dose of drug administration.
n/a